| Project/Area Number |
17K09447
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | National Institute of Infectious Diseases |
|---|
Principal Investigator |
Wakita Takaji 国立感染症研究所, 所長, 所長 (40280789)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | HCV / ＨＣＶ |
|---|
| Outline of Final Research Achievements |
Development of DAA for HCV has dramatically changed its prognosis. On the other hand, persistence of liver damage after elimination of virus and HCC are problems after viral clearance. In this study, we analyzed the ultrastructural changes and gene expression changes in liver injury using HCV infection models. HCV uninfected, HCV infected and post-HCV infected excluded cells were constructed. In these cells, there were genes that changed reversibly or irreversibly in the process of HCV infection and HCV elimination. For further study, analysis of human liver chimera mice and patient specimens reveals genes that reversibly and irreversibly change in common in the three models, and thus liver damage after DAA treatment.
|
| Academic Significance and Societal Importance of the Research Achievements |
ＨＣＶ感染は肝臓に持続感染して慢性肝炎、肝硬変、肝臓癌といった慢性肝障害を引き起こす。慢性肝障害は肝細胞のアポトーシス、リンパ球浸潤、脂肪肝などを伴う。さらに線維化が進行すると肝小葉が再構築され、肝臓の血液循環動態も変化する。従って、ＨＣＶ持続感染による肝障害はウイルス感染そのもの、および宿主の免疫反応だけによるものではなく、肝臓の組織再構築による変化も関与することが考えられる。従って、DAA治療によりウイルス排除が達成された後も、引き続き肝障害が持続し、肝発がんに至ることもあり得る。
|
